Friday, 20 Apr 2018

You are here

FDA Approves Mepolizumab for Churg-Strauss (EGPA)

The Food and Drug Administration (FDA) approved use of Nucala (mepolizumab) for use in treating adults with eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss vasculitis. This is first FDA-approved therapy specifically to treat EGPA. 

EGPA is rare with an stimated incidence of 0.11 to 2.66 cases per 1 million per year and an overall prevalence of 10.7 to 14 per 1,000,000 adults.

Nucala, an interleukin-5 antagonist monoclonal antibody, was previously approved in 2015 to treat severe asthma with an eosinophilic phenotype.  The current approval occurs because of an FDA priority review through the orphan drug program. Orphan drug designation provides incentives to assist and encourage the development of drugs for rare diseases.

Evidence for the efficacy of mepolizumab was established in a NEJM report (N Engl J Med 2017; 376:1921-1932) published in May 18, 2017.  This was a 52 week study of 136 patients with relapsing or refractory EGPA patients (on stable doses of steroids) who were given either 300 mg of mepolizumab or placebo every 4 weeks, for a year. The mepolizumab group had more remissions at both week 36 and week 48 (32% vs. 3%), had a 50% lower annualized relapse rate and more patients in the mepolizumab group (18%) were able to discontinue prednisone.

Although only half the participants treated with mepolizumab had protocol-defined remission, this novel biologic intervention represents a new and significant advance in the treatment of EGPA.

Nucala is administered as 300mg once every four weeks by subcutaneous injection

The most common adverse reactions associated with Nucala in clinical trials included headache, injection site reaction, back pain, and fatigue. There are warnings about the risk of herpes zoster, helminthic infections and avoidance during acute bronchospasm or status asthmaticus.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

IL-6 Inhibition Most Effective in Polycyclic Systemic JIA

The German Autoinflammatory Disease (AID) registry has studied the effects of the IL-6 inhibitor tocilizumab (TCZ) in systemic juvenile idiopathic arthritis (sJIA) patients and shown a clinical response rate of 35% during the first 12 weeks, and inactive disease and/or remission (with medication) in 75% at 12 months.

Rituximab May Halt ILD in Antisynthetase Syndrome Myositis

A multicenter study assessed patients with the antisynthetase syndrome (AS) and interstitial lung disease (ILD) and found that rituximab (RTX) therapy was associated with either improved or stable pulmonary outcomes in most. 

Anakinra May Attenuate Stroke Outcomes

The journal Stroke has published a trial wherein the use of subcutaneous IL-1Ra (anakinra) was shown to reduce the peripheral inflammatory response in those with an acute ischemic stroke. (Citation source: http://bit.ly/2uoNXEL)

FDA Panel Votes to Favor High Dose Xeljanz in Ulcerative Colitis

Yesterday a FDA advisory panel voted 15-0 in favor of approving Xeljanz (tofacitinib) 10 mg bid for patients with moderate to severe ulcerative colitis.

The US Food and Drug Administration’s (FDA) convened the Gastrointestinal Drugs Advisory Committee Meeting (GIDAC) to assess Pfizers supplemental new drug application for tofacitinib in adult patients with moderately to severely active ulcerative colitis (UC).

Abatacept Efficacy in JIA

Subcutaneous abatacept (Orencia) showed efficacy among children with polyarticular juvenile idiopathic arthritis (JIA) in an open-label phase III trial.